A team of researchers led by Boston University, the University of Liverpool, Public Health England, and other international agencies has discovered a biomarker that can help predict the progression of the Ebola disease: a handful of genes that are overactivated in patients who succumb to the disease.
The research, funded by the United Kingdom’s National Institute for Health Research and the US Food and Drug Administration, and published on January 19, 2017, in the journal Genome Biology, suggests a new type of blood test that while still in the preliminary stages of development, might be useful in future outbreaks to steer patients to the best treatment.
“We can get a sense of who will survive and who won’t, and we can get it earlier. This is the first study of this type ever done on this scale.”
– John Connor, a School of Medicine associate professor of microbiology at BU’s National Emerging Infectious Diseases Laboratories
Get the full story at Science Blog